Free Trial
NYSE:PRGO

Perrigo (PRGO) Stock Price, News & Analysis

Perrigo logo
$27.73 -0.21 (-0.74%)
Closing price 03:59 PM Eastern
Extended Trading
$27.73 -0.01 (-0.03%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Perrigo Stock (NYSE:PRGO)

Key Stats

Today's Range
$27.63
$28.06
50-Day Range
$23.53
$29.50
52-Week Range
$23.14
$33.46
Volume
1.36 million shs
Average Volume
1.44 million shs
Market Capitalization
$3.78 billion
P/E Ratio
N/A
Dividend Yield
4.18%
Price Target
$33.00
Consensus Rating
Hold

Company Overview

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Remove Ads

Perrigo Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

PRGO MarketRank™: 

Perrigo scored higher than 97% of companies evaluated by MarketBeat, and ranked 20th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Perrigo has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Perrigo has only been the subject of 2 research reports in the past 90 days.

  • Read more about Perrigo's stock forecast and price target.
  • Earnings Growth

    Earnings for Perrigo are expected to grow by 19.53% in the coming year, from $2.56 to $3.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Perrigo is -23.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Perrigo is -23.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Perrigo has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Perrigo's valuation and earnings.
  • Percentage of Shares Shorted

    3.37% of the float of Perrigo has been sold short.
  • Short Interest Ratio / Days to Cover

    Perrigo has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Perrigo has recently decreased by 15.06%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Perrigo is a leading dividend payer. It pays a dividend yield of 4.10%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Perrigo has been increasing its dividend for 23 years.

  • Dividend Sustainability

    Based on earnings estimates, Perrigo will have a dividend payout ratio of 37.91% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

  • Read more about Perrigo's dividend.
  • Percentage of Shares Shorted

    3.37% of the float of Perrigo has been sold short.
  • Short Interest Ratio / Days to Cover

    Perrigo has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Perrigo has recently decreased by 15.06%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Perrigo has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Perrigo this week, compared to 6 articles on an average week.
  • Search Interest

    14 people have searched for PRGO on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Perrigo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $214,032.00 in company stock.

  • Percentage Held by Insiders

    Only 0.70% of the stock of Perrigo is held by insiders.

  • Percentage Held by Institutions

    95.91% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Perrigo's insider trading history.
Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Perrigo Co PLC (PRGO) Shares Up 0.11% on Mar 19
Perrigo Company plc (PRGO) Stock Forecasts
Perrigo rises 16.6%
See More Headlines

PRGO Stock Analysis - Frequently Asked Questions

Perrigo's stock was trading at $25.71 at the start of the year. Since then, PRGO stock has increased by 7.9% and is now trading at $27.7350.
View the best growth stocks for 2025 here
.

Perrigo Company plc (NYSE:PRGO) released its quarterly earnings data on Thursday, February, 27th. The company reported $0.93 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.01. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.20 billion. Perrigo had a positive trailing twelve-month return on equity of 7.38% and a negative net margin of 3.64%.

Perrigo subsidiaries include these companies: HRA Pharma, Ranir, Laboratoire de la Mer SAS, Geiss Destin & Dunn, ScarAway, Omega Pharma, Elan Corporation, and others.

Top institutional shareholders of Perrigo include Vanguard Group Inc. (10.90%), Price T Rowe Associates Inc. MD (5.75%), Dimensional Fund Advisors LP (5.12%) and Deprince Race & Zollo Inc. (3.34%). Insiders that own company stock include Svend Andersen, Ronald Craig Janish, Geoffrey M Parker, James E Dillard III, Robert Willis, Patrick Lockwood-Taylor, Alison Ives, Grainne Quinn, Eduardo Guarita Bezerra, Katherine C Doyle, Jeffrey B Kindler, Thomas Farrington and Murray S Kessler.
View institutional ownership trends
.

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Perrigo investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
2/27/2025
Ex-Dividend for 3/25 Dividend
3/07/2025
Today
3/24/2025
Dividend Payable
3/25/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:PRGO
Employees
8,900
Year Founded
1887

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$42.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+19.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
10.82
P/E Growth
N/A
Net Income
$-12,700,000.00
Pretax Margin
-4.67%

Debt

Sales & Book Value

Annual Sales
$4.37 billion
Cash Flow
$5.78 per share
Price / Cash Flow
4.79
Book Value
$35.19 per share
Price / Book
0.79

Miscellaneous

Free Float
135,473,000
Market Cap
$3.78 billion
Optionable
Optionable
Beta
0.48

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:PRGO) was last updated on 3/24/2025 by MarketBeat.com Staff
From Our Partners